Product Description
Midazolam injection is used before medical procedures and surgery to cause drowsiness, relieve anxiety, and prevent any memory of the event. It is also sometimes given as part of the anesthesia during surgery to produce a loss of consciousness. Midazolam injection is also used to cause a state of decreased consciousness in seriously ill people in intensive care units (ICU) who are breathing with the help of a machine. Midazolam injection is in a class of medications called benzodiazepines. It works by slowing activity in the brain to allow relaxation and decreased consciousness. (Sourced from: https://medlineplus.gov/druginfo/meds/a609014.html)
Mechanisms of Action: GABA Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Epilepsy | Seizures | Anastesia Related | Status Epilepticus
Known Adverse Events: Headache | Apnea | Status Epilepticus | Airway Obstruction
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, China, Germany, Hungary, South Africa, Sweden, United Kingdom, United States
Active Clinical Trial Count: 49
Highest Development Phases
Phase 3: Other|Seizures
Phase 2: Cataract
Phase 1: Body Weight Changes|Breast Cancer|COVID-19|Chronic Obstructive Pulmonary Disease|Drug Hypersensitivity|Gastrointestinal Cancer|Gastrointestinal Stromal Tumors|Gout|Healthy Volunteers|Heart Failure, Chronic|Heart Failure, Systolic|Helicobacter Infections|Hepatitis B, Chronic|Influenza, Human|Malaria|Male Breast Cancer|Non-Small-Cell Lung Cancer|Obesity|Overweight|Pain Unspecified|Prostate Cancer|Psoriasis|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
U1111-1307-0132 | P1 |
Active, not recruiting |
Overweight|Obesity |
2025-11-12 |
|
D8532C00006 | P1 |
Recruiting |
Male Breast Cancer |
2025-02-23 |
|
HM005PS1S08 | P1 |
Not yet recruiting |
Psoriasis |
2025-02-12 |
|
J5C-MC-FOAF, DC-853104 | P1 |
Recruiting |
Healthy Volunteers |
2024-12-31 |